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SUMMARY 35	
α2-Macroglobulin (α2M) has many functions in vertebrate physiology. In order to 36	
understand the basis of such functions, high-resolution structural models of its 37	
conformations and complexes with interacting partners are required. In an attempt to grow 38	
crystals that diffract to high or medium resolution, we isolated native human α2M (hα2M) 39	
and its counterpart from chicken egg-white (ovostatin) from natural sources. We developed 40	
specific purification protocols, and modified the purified proteins either by deglycosylation 41	
or by conversion to their induced forms. Native proteins yielded macroscopically 42	
disordered crystals or crystals only diffracting to very low resolution (>20Å), respectively. 43	
Optimization of native hα2M crystals by varying chemical conditions was unsuccessful, 44	
while dehydration of native ovostatin crystals improved diffraction only slightly (10Å). 45	
Moreover, treatment with several glycosidases hindered crystallization. Both proteins 46	
formed spherulites that were unsuitable for X-ray analysis, owing to a reduction of protein 47	
stability or an increase in sample heterogeneity. In contrast, transforming the native 48	
proteins to their induced forms by reaction either with methylamine or with peptidases 49	
(thermolysin and chymotrypsin) rendered well-shaped crystals routinely diffracting below 50	
7Å in a reproducible manner.  51	
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INTRODUCTION 69	
The pan-protease inhibitor α2-macroglobulin (α2M), together with α1-macroglobulin, 70	
components of the complement cascade (C3, C4 and C5) and pregnancy zone protein, 71	
constitute a family of proteins present in all metazoans (Rehman et al., 2013). They 72	
contribute to innate immunity and share similar biochemical and structural characteristics, 73	
indicating a close evolutionary relationship and a common ancestor (Sottrup-Jensen, 74	
1989; Janssen et al., 2005; Baxter et al., 2007; Fredslund et al., 2008; Marrero et al., 75	
2012). Only recently, proteins of this family have been identified in Gram-negative 76	
bacteria, perhaps as a result of more than one horizontal gene transfer event from 77	
metazoans (Budd et al., 2004; Doan and Gettins, 2008; Kantyka et al., 2010; Robert-78	
Genthon et al., 2013). 79	
 Human α2M (hα2M) is a 720-kDa homotetrameric glycoprotein found abundantly in 80	
blood plasma. It affords defense against invasive bacteria by trapping their proteases and 81	
hampering therefore their successful invasion (Armstrong, 2001). In addition, it regulates 82	
endogenous peptidases, and imbalance of its activity leads to several major human 83	
diseases (Woessner, 1999; Saunders and Tanzi, 2003; Schaller and Gerber, 2011). 84	
Besides its importance as a peptidase inhibitor, α2M also interacts with several proteins, 85	
including defensins, cytokines, growth factors and transferrin, thus participating in diverse 86	
and complex regulatory functions (Rehman et al., 2013). 87	
The peptidase inhibitory function of α2M was recently characterized as a new 88	
version of the “Venus flytrap” mechanism (Meyer et al., 2012). Invasive peptidases are 89	
confined inside a molecular cage and their action is inhibited by steric hindrance (Marrero 90	
et al., 2012). The molecular mechanism starts when a peptidase enters the native inhibitor 91	
particle through a narrow opening and cleaves two of the four bait regions of α2M (Sottrup-92	
Jensen et al. 1989). This induces a large conformational change, which entraps the 93	
peptidase within α2M. At the same time, in a coordinated manner, a second mechanism is 94	
induced involving a highly reactive cysteine-glutamine thioester bond, which covalently 95	
binds exposed lysines on the attacking peptides, ensuring their entrapment. Induction then 96	
exposes a carboxy-terminal domain, the “receptor binding domain”, on the tetramer 97	
surface (Sottrup-Jensen 1989). As a result, α2M is recognized by cell-surface receptors 98	
and the complex is internalized by endocytosis and degraded in the lysosomes within 99	
minutes of complex formation (Williams et al., 1994). Several α2Ms have been 100	
characterized to date, all sharing the same trapping mechanism. Some, such as ovostatin, 101	
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lack an active thioester bond, but they are equally efficient peptidase inhibitors (Rehman et 102	
al., 2013).  103	
Structural characterization of α2M has been extensively addressed since its first 104	
isolation by Cohn and co-workers (Cohn et al., 1946). Many attempts to obtain X-ray 105	
structural models at high resolution were unsuccessful owing to the poor diffracting 106	
properties of the crystals (Andersen et al., 1991; Andersen et al., 1994). Therefore, most 107	
research was centred on cryo-electron microscopy models (Stoops et al., 1991; Kolodziej 108	
and Schroeter, 1996). Only recently, a 4.3Å resolution model was reported, in which 109	
structural details of the methylamine-induced α2M (α2M-MA) were described (Marrero et 110	
al., 2012). However, in order to understand its mechanism of action and influence in 111	
physiology, higher resolution models are required, including that of the native form and 112	
models of complexes with peptidases or other interacting molecules. In this context, we 113	
examined two α2M inhibitor homologues: one from human (hα2M) and the other from 114	
chicken egg-white (ovostatin). We assayed several strategies to obtain better diffracting 115	
crystals, and thus higher resolution models, in a reproducible manner.  116	
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 136	
 137	
MATERIALS AND METHODS 138	
 139	
Isolation and purification of hα2M and ovostatin. Hα2M was isolated from blood plasma 140	
from individual donors and purified essentially as described (Sottrup-Jensen et al., 1980; 141	
Marrero et al., 2012). Briefly, hα2M in phosphate-buffered saline (pH7.2) was subjected to 142	
anion-exchange chromatography in a Q Sepharose column (2.5x10cm) previously 143	
equilibrated with 15% buffer A (20mM Hepes, 1M NaCl, pH7.5). A gradient of 20% to 30% 144	
buffer A was applied over 150min and fractions were collected in three pools. Selected 145	
samples were further fractionated in a TSKgel DEAE-2SW column (TOSOH Bioscience) 146	
equilibrated with 2% of buffer B (20mM Tris-HCl,1M NaCl, pH7.5). A gradient of 7% to 147	
20% buffer B was applied over 30ml and samples were collected and pooled. 148	
Subsequently, each pool was concentrated and subjected to size-exclusion 149	
chromatography in a Superose 6 Prep-Grade column (GE Healthcare Life Sciences) in 150	
buffer C (20mM Tris-HCl, 150mM NaCl, pH7.5).  151	
Ovostatin was isolated from egg-white from a single hen and purified as previously 152	
described (Nagase et al., 1983). Briefly, after an initial clarification step with 5.5% 153	
PEG8000 and removal of aggregates by centrifugation, ovostatin was collected by 154	
precipitation with 10% PEG8000 and resuspended in 50mM trisodium citrate, 400mM 155	
NaCl, pH6.5. The protein solution was incubated overnight, and precipitated mucins were 156	
removed in a Sorvall centrifuge (Thermo Scientific) at 16.000xg for 20min at 4oC. 157	
Subsequently, the supernatant was passed through a 0.22µm pore size filter (Millipore) 158	
and injected into a HiPrep 26/60 Sephacryl S200 column (GE Healthcare Life Sciences). 159	
Fractions from the void volume were collected and further purified by anion-exchange 160	
chromatography in a 6ml Resource Q column (GE Healthcare Life Sciences) with a 161	
gradient from 14% to 24% of buffer B in 10 column volumes. Selected samples were 162	
purified with a TSKgel DEAE-2SW column using a linear gradient from 2% to 25% of 163	
buffer B within 40 column volumes. The protein was finally polished with a Superose 6 164	
Prep-Grade in buffer C. 165	
Proteins were routinely concentrated with Vivaspin 2 centrifugal filter devices 166	
(Sartorius Stedim Biotech) with a molecular-mass cut-off of 30 or 50kDa. All purification 167	
steps were performed at 4oC. 168	
 169	
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 170	
Expression and purification of glycosidases. All expression trials were performed in 171	
lysogeny broth supplemented with 100µg/ml ampicillin. Glutathione-S-transferase fusions 172	
of peptide-N-glycosidase F (PNGase F) and endo-β-N-acetyl-glucosaminidase F1 (Endo 173	
F1) (kindly provided by Yoav Peleg, Israel) were expressed in E. coli M15 cells overnight 174	
at 20oC or for 5h at 37oC, respectively (Grueninger-Leitch et al., 1996). Proteins were 175	
purified by affinity chromatography with a GST-Hitrap column (GE Healthcare Life 176	
Sciences). Endo F2 and Endo F3 (kindly provided by Patrick Van Roey, USA) fused to 177	
maltose-binding protein were expressed as inclusion bodies in E. coli BL21 (DE3) cells for 178	
6h at 37oC and subsequently isolated, refolded and purified by anion-exchange 179	
chromatography as previously described (Reddy et al., 1998; Waddling et al., 2000). Cells 180	
were routinely broken with a cell disrupter (Constant Cell Disruption Systems) at a 181	
pressure of 1.35Kbar for soluble proteins and 1.9Kbar for inclusion bodies. Purified 182	
proteins were stored at -20oC after a buffer exchange with a PD10 column (GE Healthcare 183	
Life Sciences) to 50mM Tris-HCl pH8.0, 25% glycerol for PNGase F or 50mM trisodium 184	
citrate pH5.5, 25% glycerol for Endo F1, F2 and F3. Activity of glycosidases was verified 185	
with the glycoprotein ribonuclease B (New England Biolabs) at a weight ratio of 1:5 186	
(enzyme:substrate) and a final substrate protein concentration of 0.5mg/ml. Reactions 187	
were incubated overnight at 4oC and analysed by SDS-PAGE. Acetyl-neuraminyl 188	
hydrolase (sialidase) from Clostridium perfringens was purchased from New England 189	
BioLabs.  190	
 191	
 192	
Induction and deglycosylation of hα2M and ovostatin. Native hα2M was converted to 193	
the induced form by treatment with 200mM methylamine hydrochloride (MA) for 30min at 194	
room temperature in 100mM Tris-HCl, 150mM NaCl, pH8.0. Reactions of hα2M or 195	
ovostatin with different ratios of Bacillus thermoproteolyticus thermolysin or chymotrypsin 196	
from bovine pancreas (both from Sigma-Aldrich) were performed for 1h at room 197	
temperature in buffer D (50mM Tris-HCl, 150mM NaCl, pH7.5), except for reactions with 198	
thermolysin, in which 5mM CaCl2 was also included. Reactions were stopped with 4mM 4-199	
(2-aminoethyl) benzenesulfonyl fluoride (Pefabloc SC, FLUKA) for chymotrypsin or 5mM 200	
1,10-phenanthroline for thermolysin. 201	
 Desialylation trials were performed at an hα2M or ovostatin protein inhibitor 202	
concentration of 1mg/ml in 50µl reaction volumes with 20mM Hepes, 25mM NaCl, pH7.5 203	
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as buffer. Different sialidase units (from 1 to 50) were tested and the reactions were 204	
incubated overnight at 37oC. Deglycosylation of the proteins was performed overnight at 205	
4oC in weight ratios ranging from 1:10 to 1:500 of glycosidase:inhibitor. Reactions with 206	
PNGase F and Endo Fs were performed, respectively, in 50mM Tris-HCl, 50mM NaCl, 207	
pH7.5 and 50mM Hepes, 50mM NaCl, pH6.5. Subsequently, glycosidases were trapped 208	
by affinity chromatography in a GST-Trap or MBP-Trap column, and deglycosylated α2M 209	
samples were collected from the flow-through. Modified inhibitors were further purified by 210	
anion-exchange chromatography and size exclusion chromatography as described above.  211	
 212	
 213	
Thermal shift assays. Aliquots were prepared by mixing 7.5µl of 300x Sypro Orange dye 214	
(Molecular Probes), 5µl protein solution (2.5-5mg/ml in buffer B), and 37.5µl of buffer B. 215	
The samples were analyzed in an iCycler iQ Real Time PCR Detection System (BioRad) 216	
by using 96-well PCR plates sealed with optical tape. Samples were heated from 20°C to 217	
90oC at a rate of 1oC/min and the change in absorbance (λex=490nm; λem=575nm) was 218	
monitored over time. The melting temperature (Tm) was determined for the native and 219	
deglycosylated forms of the inhibitors.  220	
 221	
 222	
Proteolytic activity assays. Proteolytic activity with thermolysin or chymotrypsin trapped 223	
in α2M complexes was routinely measured with the fluorescence-based EnzCheck assay 224	
kit containing BODIPY FL-casein (10µg/ml) as a fluorescent conjugate (Invitrogen) at 225	
λex=485nm and λem=528nm by using a microplate fluorimeter (FLx800, Biotek). Reactions 226	
were performed in buffer D at room temperature (Goulas et al., 2011). 227	
 228	
 229	
Crystallization, crystal optimization and data analysis. Initial crystallization assays 230	
were performed by the sitting-drop vapor diffusion method with protein concentrations 231	
ranging from 4mg/ml to 20mg/ml. Reservoir solutions were prepared by a Tecan robot and 232	
100nl crystallization drops were dispensed on 96×2-well MRC plates (Innovadyne) by a 233	
Cartesian (Genomic Solutions) nanodrop robot at the IBMB/IRB High-Throughput 234	
Crystallography Platform (PAC) of the Barcelona Science Park. Plates were stored in a 235	
crystal-farm (Nexus Biosystems) at constant temperatures (4oC and 20oC). Successful 236	
crystallization hits were scaled up to the microliter range with 24-well Cryschem or VDX 237	
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crystallization dishes (Hampton Research) in sitting or hanging drop format, respectively. 238	
Conditions were optimized by varying the initial crystallization conditions and protein 239	
concentration, by performing crystal seeding and by including different additives (Hampton 240	
Research). Controlled crystal dehydration was performed with the Free Mounting System 241	
(FMS; Proteros Biostructures) in an adjustable and reproducible stream of humidified gas, 242	
with relative humidity ranging from 70%-98% in 2% increments. A cryocooling protocol 243	
was established consisting of either successive passages through reservoir solution 244	
containing increasing concentrations of glycerol (up to 20%) or direct immersion of crystals 245	
mounted on a loop in Fomblin Y oil. Thereafter, crystals were flash-vitrified in liquid 246	
nitrogen and stored. Crystals were checked for X-Ray diffraction at beam lines ID23-1 and 247	
ID23-2 of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) at 100K, 248	
which were provided with an ADSC Q315R CCD detector and a Mar/Rayonix 3x3 Mosaic 249	
225 detector, respectively. Access to the synchrotron was assigned within the block 250	
allocation group “BAG Barcelona.” Collected datasets were processed with the 251	
XDS/XSCALE package (Kabsch, 2010). 252	
 253	
 254	
Miscellaneous. Denatured protein samples were analyzed by 10%-15% Tricine-SDS-255	
PAGE (Schägger, 2006) and native proteins by 5% Tris-glycine native PAGE (Haider et 256	
al., 2011) and stained with Coomassie-brilliant blue. 257	
Protein concentrations were routinely determined by absorbance at λ=280nm, and 258	
wherever necessary corrected by the BCA protein assay method (Thermo Scientific) using 259	
bovine serum albumin as a standard. Protein identification by peptide mass fingerprinting 260	
was performed at the Protein Chemistry Facility of Centro de Investigaciones Biológicas in 261	
Madrid (Spain). 262	
 263	
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 272	
RESULTS 273	
 274	
Deglycosylation of hα2M and ovostatin. The inhibitors were isolated from individual 275	
human donors (hα2M) or from eggs from a single chicken (ovostatin), and the proteins 276	
were purified by a range of chromatographic techniques, applying strict fractionation to 277	
maximize sample homogeneity and purity (Fig. 1A). At this point, both inhibitors were 278	
subjected to deglycosylation with several glycosidases of variable substrate specificity: 279	
sialidase, PNGase F and three Endo Fs (F1, F2 and F3). In particular, treatment of 280	
ovostatin with increasing amounts of sialidase had no detectable effect as evaluated by 281	
native PAGE (Fig. 1B). In contrast, hα2M was efficiently desialylated in overnight reactions 282	
with one sialidase unit per 50ng of protein, showing a reduction in its electrophoretic 283	
mobility (Fig. 1C). Digestion with PNGase F or Endo Fs induced a variety of changes in 284	
both proteins, thus indicating (at least partial) removal of attached glycosides. In the case 285	
of hα2M, the effect of PNGase F was detectable only in native PAGE, and was especially 286	
strong at high glycosidase:inhibitor ratios (1:10; see Fig. 1D). On the other hand, Endo Fs 287	
at ratios ranging from 1:100 to 1:500 efficiently deglycosylated hα2M, as shown by SDS-288	
PAGE (Fig. 1F). Moreover, digestion with Endo F2 and F3 gave more homogeneous 289	
samples than with Endo F1. In ovostatin, deglycosylation was observed in similar level 290	
with all the enzymes except Endo F3, which induced minor changes (Fig. 1G). As with 291	
hα2M, a larger amount of PNGase F was required to achieve detectable modification in 292	
comparison to Endo Fs. Deglycosylation of both proteins was even stronger when all the 293	
enzymes were used in combination, thus substantiating a synergistic effect. 294	
Deglycosylation was also assessed by a comparative thermal shift assay, in which the 295	
temperature of midtransition (Tm) of native and deglycosylated native forms were recorded 296	
(Fig. 1H). The Tm of the latter species was systematically lower than that of the former, 297	
thus indicating a reduction in thermal stability by ablation of sugars.  298	
 299	
 300	
Induction of hα2M and ovostatin. Native inhibitors were converted to their activated 301	
forms by treatment with peptidases. In addition, hα2M was also activated with methylamine 302	
but ovostatin, which lacks a thioester bond, was not. Deglycosylated hα2M showed the 303	
characteristic change in electrophoretic mobility in native PAGE after activation by 304	
breaking the thioester bond with methylamine, indicating that deglycosylation had no 305	
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significant effect on the behavior of the protein (Fig. 1E) (Barrett et al., 1979). Also, the 306	
inhibitory function of the protein was unaffected, as observed after reaction with 307	
thermolysin at various concentrations (Fig. 1I). Proteolysis resulted in the formation of a 308	
pair of bands that ran as 75- and 95-KDa species in SDS-PAGE, as reported elsewhere 309	
(Sottrup-Jensen et al., 1981). At molar ratios of protease:inhibitor higher than 2:1, 310	
complete digestion of hα2M was observed, accompanied by a sudden increase in the 311	
proteolytic activity due to inhibition release. Similarly glycosylated ovostatin was also 312	
activated with either chymotrypsin or thermolysin, which split the protein into the two 313	
characteristic bands, accompanied by an increase in the remaining activity at ratios higher 314	
than 2:1 (Fig. 1J). 315	
 316	
 317	
Crystallization and X-ray diffraction. Crystallization trials of native Hα2M yielded small 318	
irregular crystals (Fig. 2A and Table 1). Optimization by varying chemical reagents or 319	
crystal seeding was unsuccessful. Moreover, after deglycosylating the protein, only 320	
spherulites unsuitable for X-ray diffraction studies were obtained under various conditions 321	
(Fig. 2B). Subsequently, conversion of the proteins to their induced forms, by either 322	
methylamination or reaction with thermolysin, resulted in several distinct well-shaped 323	
crystals (Fig. 2C, D, E and F). Several hundreds of these were collected and tested for 324	
diffraction: they routinely yielded diffraction up to 7-8Å (Table 1). Exceptionally, one crystal 325	
coming from glycosylated and methylamine-activated protein yielded a complete dataset to 326	
5.9Å resolution (Table 2 and Fig. 3A). This was isomorphous to the single crystal obtained 327	
previously, which was used to solve the structure to 4.3Å resolution (Marrero et al., 2012). 328	
Native ovostatin, in turn, yielded nicely shaped crystals which, however, only 329	
diffracted to >20Å (Fig 2G). Accordingly, several optimization trials were performed by 330	
varying the crystallization conditions, screening several additives and modifying the protein 331	
by deglycosylation, but with no success. However, after a systematic trial to dehydrate the 332	
crystals by overnight incubation in increasing concentrations of glycerol, an overall 333	
improvement of the diffraction to 10Å was observed. Further, based on this observation, a 334	
controlled dehydration experiment with the Free Mounting System was performed, during 335	
which crystals were treated in relative humidity conditions between 70% and 98%. 336	
Unfortunately, this strategy was also unsuccessful. The complex of induced ovostatin with 337	
thermolysin, in turn, yielded only thin, fragile needles that did not diffract (Fig 2H). In 338	
contrast, ovostatin induced with chymotrypsin gave well-shaped crystals (Fig. 2I), which 339	
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diffracted to better than 7Å (Fig. 3B). One complete dataset was collected and processed 340	
to 6.7Å, revealing an orthorhombic space group and four molecules per asymmetric unit 341	
(Table 2). 342	
 343	
 344	
DISCUSSION 345	
Due to their significance in vertebrate physiology, the peptidase inhibitors of the α2M family 346	
of proteins have been subjected to extensive research for almost seventy years. One of 347	
the aims is to obtain medium- or high-resolution structural models to explain their 348	
mechanism of function, which was achieved only recently with methylamine-treated 349	
glycosylated hα2M (Marrero et al., 2012). Over the last few decades, besides the 350	
technological advances in protein crystallography through the routine availability of 351	
synchrotron radiation and sensitive CCD and pixel detectors, several efforts have focused 352	
on improving crystal quality and achieving reproducible results, but without major 353	
breakthroughs. The weak crystal diffraction can be attributed mainly to sample 354	
heterogeneity owing to glycosylation and the intrinsic flexibility of target proteins (Andersen 355	
et al., 1991; Andersen et al., 1994). 356	
In an attempt to increase the resolution of our current hα2M model, we examined 357	
two orthologs—one from human and the other from chicken— which were isolated from 358	
fluids of different function and had low sequence similarity (<44.5%). Both proteins were 359	
isolated and purified from individual sources to maximize sample homogeneity, an 360	
important step to ensure a protein sample as homogenous as possible and to avoid 361	
heterogeneity associated with raw material of various origins. However, this did not 362	
provide suitable crystals for hα2M or ovostatin. A significant reproducible improvement in 363	
diffraction was observed after dehydration of ovostatin crystals. This indicated that the 364	
crystals had a large water content and loose packing, which are common problems 365	
associated with low resolution and poor-quality diffraction, as reported  for several protein 366	
crystals in the past (Andersen et al., 1991; Heras and Martin, 2005). In parallel, local 367	
disorder in crystal packing, perhaps due to slightly different conformations of segments of 368	
the eleven subunits of individual α2M tetramers, may also explain their regularly-shaped or 369	
low diffracting crystals. α2M has two different forms, depending on whether it is induced by 370	
proteases. The induced form adopts a more close conformation that is more robust and 371	
has lower solvent content (Barrett et al., 1979; Marrero et al., 2012). In accordance with 372	
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these observations, activation of the glycosylated proteins with either methylamine or 373	
peptidases reproducibly yielded crystals diffracting to better than 7Å. 374	
Hα2M and ovostatin are glycoproteins with a high carbohydrate content (Dunn and 375	
Spiro, 1967; Nielsen et al., 1994; Paiva et al., 2010). Glycosylation is an important 376	
posttranslational modification in eukaryotic proteins, and it plays role in proper protein 377	
folding and stability but also in protein function (Walsh et al., 2005; Chang et al., 2007). In 378	
contrast to the positive effect on protein folding and function, glycosylation is, in general, 379	
highly deleterious for crystallogenesis, since it hinders the necessary crystal contacts or 380	
introduces microheterogeneity into the protein sample (Baker et al., 1994; Grueninger-381	
Leitch et al., 1996). Therefore, hα2M and ovostatin were treated with various glycosidases, 382	
all of which removed glycosides to a certain extent. The best results were obtained after 383	
combined use of PNGase F and the three Endo Fs assayed. Sialidase was effective on 384	
hα2M but not on ovostatin. However, as removal of glycosides with these enzymes 385	
simultaneously entailed removal of the sialic acid moieties at the terminating branches of 386	
N-glycans (Varki and Schauer, 2009), sialidase alone was not used for subsequent 387	
experiments with hα2M. Crystallization trials with deglycosylated forms of both native hα2M 388	
and ovostatin only resulted in spherulites in the best cases. This indicated that 389	
deglycosylation either increased heterogeneity or exacerbated protein stability, factors 390	
which are highly correlated with crystallization probability (Ericsson et al., 2006). 391	
Overall, the crystallization trials presented here indicate that modification of the 392	
α2M-like protein inhibitors by glycosidases is not a favorable approach. Only conversion of 393	
the protein to the activated form rendered more reproducible results, although still at low 394	
resolution. Therefore, more crystallization conditions and methods need to be tested in 395	
order to obtain suitable samples for high resolution diffraction studies.  396	
  397	
 398	
 399	
 400	
 401	
 402	
 403	
 404	
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 540	
 541	
Table 1: Crystallization and X-ray diffraction of crystals. 542	
 543	
1MIB buffer is produced by mixing sodium malonate, imidazole, and boric acid in the molar ratios 2:3:3. 544	
Ha2M, human a2-macrogobulin. 545	
 546	
Protein Crystallization conditions Crystal morphology Diffraction resolution 
Native hα2M 
 
0.2M lithium sulfate, 
0.1M imidazole pH8.0 
10% PEG 3000 
At 20oC 
Irregular crystals - 
Native hα2M deglycosylated - Spherulites - 
Hα2M-MA 
0.1M Tris-HCl pH7.5 
15% PEG 3350 
At 20oC 
Rectangular prisms 
Two dimensional plates 5.9Å 
0.2M ammonium citrate pH6.4 
15% PEG 5000 MME 
At 20oC 
Hα2M-MA deglycosylated 
0.2M ammonium citrate pH6.4 
15% PEG 5000 MME 
At 20oC 
Rectangular prisms 7Å 
Hα2M deglycosylated in 
complex with thermolysin 
0.1M MIB1 pH8.0 
25% PEG 1500 
At 20oC 
Rectangular prisms 8Å 
Native ovostatin 
0.2M NaCl 
0.1M phosphate citrate pH5.0 
10%  PEG 3000 
At 4oC 
Square pyramids 10Å 
Native ovostatin 
deglycosylated - Spherulites - 
Ovostatin in complex with 
chymotrypsin 
0.1M MIB pH4.0 
22% PEG 1500 
At 4oC 
Square pyramids 6.7Å 
Ovostatin in complex with 
thermolysin 
0.1M sodium acetate pH4.6 
8% PEG 4000 
At 4oC 
Thin needles - 
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Table 2: Crystallographic data. 
Dataset hα2M-MA Ovostatin in complex with chymotrypsin 
Space group / cell constants (a, b, and c, in Å) P212121 / 130.1 262.7 281.5 C222 / 287.3 478.7 367.2 
Wavelength (Å) 0.97917 0.97239 
No. of measurements / unique reflections 160,377 / 25,026 615,133 / 45,268 
Resolution range (Å) (outermost shell)a 49.23– 5.97 (6.66 – 5.97) 49.78 – 6.72 (7.34 – 6.72) 
Completeness (%) 99.2 (99.7) 99.6 (100) 
Rmergeb 0.080 (0.628) 0.143 (0.801) 
Rr.i.m. (=Rmeas)b 0.087 (0.68) 0.148 (0.832) 
Average intensity (<[<I> / σ(<I>)]>) 19.3 (3.2) 15.9 (4.08) 
B-Factor (Wilson) (Å2) / Average multiplicity 293.5/ 6.4 (6.6) 335.3/ 13.6 (13.8) 
aValues in parentheses refer to the outermost resolution shell. 
bRr.i.m.= Σhkl(nhkl /[nhkl-1]1/2)Σi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl) where Ii(hkl) is the i-th intensity measurement and nhkl the number of 
observations of reflection hkl,including symmetry-related reflections, and <I(hkl)> its average intensity. Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| 
/ ΣhklΣiIi(hkl). 
 
Goulas	et	al.	
20	
	
[Figure Legends] 
Figure 1. Modification of native hα2M and ovostatin by deglycosylation or activation to the 
induced form. (A) SDS-PAGE of hα2M and ovostatin after isolation and purification from 
individual sources. (B)(C) Desialylation of ovostatin and hα2M, respectively. Protein 
samples were incubated in the absence (lane 1) or presence (lane 2) of sialidase and 
analyzed by native PAGE. (D) Deglycosylation of hα2M by PNGase F. Purified protein 
(lane 1) was digested with PNGase F (lane 2) in a weight ratio of 10:1 and analyzed by 
native PAGE. (E) Activation of hα2M by methylamine. Deglycosylated hα2M (lane 1) was 
induced with methylamine (lane 2) and analyzed by native PAGE. (F)(G) Deglycosylation 
of hα2M and ovostatin by glycosidases. Protein samples were incubated in the absence 
(lanes 1 and 7) or presence of either PNGase F (lane2) or different Endo Fs (F1, F2 and 
F3) individually (lanes 3-5) or in a single reaction (lane 6) and subsequently analyzed by 
SDS-PAGE or native PAGE, respectively. (H) Thermal shift curves of native hα2M and 
ovostatin before (black lines) and after deglycosylation (gray lines). Values are 
represented as means of three experiments. (I)(J) Activation of hα2M and ovostatin by 
peptidases. Proteins were incubated with thermolysin or chymotrypsin at various ratios 
and analyzed by SDS-PAGE. The residual proteolytic activity (in box) against BODIPY FL-
casein is expressed as percentage of the activity in absence of α2M. Reactions were kept 
30min at room temperature before fluorescence measurements.  
  
 
Figure 2. Protein crystals of native and induced hα2M and ovostatin. (A) Irregularly-
shaped crystals of native hα2M. (B) Spherulites formed in crystallization drops with 
deglycosylated native hα2M. (C)(D) Prism-shaped crystals and two dimensional plates of 
methylamine induced hα2M. (E)(F) Prism-shaped crystals of deglycosylated hα2M in 
complex with thermolysin. (G) Pyramid-shaped crystals of native ovostatin. (H) Needle-
shaped crystals of ovostatin in complex with thermolysin. (I) Pyramid-shaped crystals of 
ovostatin in complex with chymotrypsin. 
 
 
Figure 3. Images of the diffraction pattern of (A) hα2M and (B) ovostatin crystals after 
exposure to synchrotron radiation. Both images were obtained after 1o rotation and 
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exposure for 0.5sec or 20sec at 100% transmission in ID23-1 or ID29, respectively. Black 
circles indicate the diffraction resolution.  



